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Antiangiogenic therapy is theoretically a promising anticancer approach but does not always produce signiﬁcant tumor control.
Combinations of antiangiogenic therapies are therefore being investigated as strategies to enhance clinical beneﬁt. Common
targets for angiogenic blockade include endothelial speciﬁc receptors, such as Tie2/Tek, which signal blood vessel stabilization
via recruitment and maturation of pericytes. Here, we report on the eﬀects of targeted Tie2 antiangiogenic therapy (TekdeltaFc)
in combination with nontargeted metronomic cyclophosphamide (LDM CTX) (reported to also act in antiangiogenic fashion) in
xenografted human melanoma. Individually, these therapies showed transient antitumor activity, but, in combination, there was
no signiﬁcant reduction in tumor growth. In addition, while TekdeltaFc caused the expected increased pericyte coverage in treated
blood vessels, LDM CTX alone or in combination with TekdeltaFc resulted in increased levels of VEGF production. Collectively,
our data highlight the complexity of molecular interactions that may take place when antiangiogenic regimens are combined.
1.Introduction
Cytotoxic chemotherapeutic drugs may have antiangiogenic
properties when administered metronomically at doses sig-
niﬁcantly lower than the maximum tolerated dose (MTD)
a n da ss u c ha p p e a rt oh a v el e s ss e v e r eo re v e na b s e n t
cytotoxic side eﬀects [1]. Cyclophosphamide (CTX), a nitro-
gen mustard alkylating agent, is clinically the most studied
drug in a low-dose metronomic chemotherapy setting [2, 3].
IncontrasttoMTD,metronomicadministrationoflow-dose
cyclophosphamide induces selective apoptosis of genetically
stable endothelial cells in tumors (hence circumventing drug
resistance) [4, 5]. In addition, studies suggest that this eﬀect
is due to overproduction of Thrombospondin-1, a well-
known, highly speciﬁc, and potent endogenous inhibitor
of angiogenesis [6, 7]. Interestingly, an inverse relation-
ship between Thrombospondin-1 and VEGF production
has been reported in cultured ovarian epithelial cells and
LDM-CTX has been shown to decrease VEGF levels in
patients with breast cancer [8], suggesting a possible rela-
tionship between VEGF expression and LDM-CTX-induced
Thrombospondin-1 expression. In general, the antitumor
eﬀects of cancers treated with LDM chemotherapy are even
more pronounced when combined with an antiangiogenic
inhibitor that targets endothelial cells speciﬁcally [9, 10].
Tie2 receptors are primarily found on endothelial cells and
are constitutively expressed in normal vasculature [11].
Thus, it was surprising when our laboratory identiﬁed blood
vessels within human cancers that lacked Tie2 expression. In
particular, malignant melanoma had the highest percentage
(∼15%) of Tie2-negative blood vessels of all cancer types
evaluated [12]. Diﬀerential expression of vascular growth
factor receptors, such as Tie2, may be due to tumor microen-
vironment conditions such as hypoxia and hypoglycemia,
which occur as a result of an imbalance between the
oxygen supply and consumption and altered energy demand
[13–15].
Heterogeneous expression of Tie2 in tumor vasculature
suggested a role for Tie2 in tumor angiogenesis, however,
elucidating the functional signiﬁcance of Tie2 expression
in tumors required the use of a speciﬁc Tie2 inhibitor
TekdeltaFc, which is an artiﬁcial extracellular domain of Tie22 Journal of Oncology
[16]. Since angiopoietins bind with high aﬃnity to Tie2
extracellular domain, we reasoned that this inhibitor should
eﬃcientlyinterferewithangiopoietin-mediated Tie2activity.
In addition, we hypothesized that the tumor microenviron-
ment is at least partially responsible for the lack of Tie2
expression observed in malignant melanoma blood vessels
and investigated the possibility that Tie2 heterogeneity is due
to severe hypoxia or hypoglycemia.
Excessive tumor angiogenesis has been associated with
poor prognosis in metastatic melanoma [17]. Thus, antian-
giogenic therapies targeting the tumor microvasculature
have been intensively used in clinical trials in combination
with the standard chemotherapeutic regimens. In one such
study, antiangiogenic low-dose paclitaxel in combination
withcelecoxibcausedsigniﬁcantdiseasestabilizationofmore
than 6 months in 15% of metastatic melanoma patients [18].
Clinical beneﬁts were also observed in melanoma patients
treated with anti-VEGF therapy, bevacizumab (Avastin),
combined with carboplatin and paclitaxel [19], or in combi-
nationwithinterferon-α-2b[20].However,todate,theeﬀect
of Tie2 inhibition on melanoma angiogenesis, alone or in
combinationwithotherantiangiogenicstrategies,hasnotyet
been explored.
Recent publications suggest a clear advantage of simul-
taneously using multiple antiangiogenic therapies in com-
bination with metronomic, low-dose chemotherapy, thus
targeting more than one endothelial cell signaling pathway
[5, 21, 22]. To determine if the response to targeted antian-
giogenic therapy such as Tie2 inhibition can be enhanced by
nontargeted antiangiogenic therapy such as LDM CTX, we
examined the impact of this combined approach on human
malignant melanoma cancer cell xenografts.
2. Methods
2.1. Cell Lines and Reagents. The human melanoma cell line
WM239 was originally isolated from a patient’s metastatic
lesion [23]. Cells were maintained in Dulbecco’s modiﬁed
Eagle’s Medium (Sigma-Aldrich) supplemented with 10%
FBS (Invitrogen), sodium pyruvate (Invitrogen), and gen-
tamicin (Invitrogen) in a humidiﬁed atmosphere at 37◦Ci n
5% CO2. Tie2 inhibitor, murine TekdeltaFc, was provided by
Amgen. Cyclophosphamide (CTX) was purchased from
Sigma Aldrich.
2.2. Growth of Tumor Xenografts. All procedures described
below were done according to the guidelines and recom-
mendations of the Canadian Council of Animal Care and
approved by the University of Guelph Local Animal Care
Committee. Tumor xenografts were established in RAG1−
immune-deﬁcient mice [24] by injecting 100μLo f0 . 1 %
BSA/PBS solution containing 1 × 106 WM239 melanoma
cells subcutaneously into the right ﬂank. Tumor growth was
measured twice weekly and tumor size estimated using the
equation: volume = length × width2 × 0.5. Once tumors
reached at least 100mm3, mice were randomly allocated
into one of four treatment groups each containing 8 mice.
Mice were treated for 14 days as follows: group 1 received
250μgTekdeltaFcas250μLi.p.every3days;group2received
low-dose cyclophosphamide in drinking water (equivalent
to 30mg/kg/day; water was changed twice weekly); group
3 received both TekdeltaFc every 3 days and low-dose
cyclophosphamide in drinking water; group 4 control mice
received 250μLi.p. injections of sterile PBS every 3 days and
untreated drinking water. Tumor growth was measured for
the duration of the trial every 3-4 days.
One hour prior to euthanasia, mice were injected i.p.
with 150mg/kg Hypoxyprobe-1 (Chemicon International
Inc.). Mice were euthanized by CO2 asphyxiation followed
by cervical dislocation. Tumors were dissected from the
surrounding tissue and cut into pieces, embedded in OCT
cryomatrix (Fisher Scientiﬁc), and snap frozen in liquid
nitrogen, ﬁxed in 4% paraformaldehyde (USB Corpora-
tion) for 24h and paraﬃn embedded, or snap frozen in
liquid nitrogen and stored at −80◦Cf o rf u t u r ep r o t e i n
isolation.
2.3. Quantiﬁcation of Tumor Hypoxic and Necrotic Areas.
Paraformaldehyde-ﬁxed paraﬃn-embedded 8μm thick sec-
tions were deparaﬃnized, and sodium citrate antigen retrie-
val (10mM, pH = 6.0, boiled for 8 minutes then cooled in
buﬀer at RT for 15min) was performed. Following antigen
retrieval, sections were washed and blocked ﬁrst with Dako
protein-free block (Dako) for 15 minutes and then with
5% normal goat serum (Sigma-Aldrich) for 30 minutes.
Next, 3% hydrogen peroxide (Fisher Scientiﬁc) was used for
15 minutes to block endogenous peroxidase activity, then
sectionswerewashedandincubatedinmouseHypoxyprobe-
1 antibody (Chemicon International) (1:50) overnight at
4◦C, followed by goat antimouse biotinylated secondary
antibody (1:200) for 30 minutes. Sections were washed and
treated with R.T.U. Vectastain Elite ABC reagent (Vector) for
30 minutes followed by incubation with substrate reagent
diaminobenzidine (DAB) for 2 minutes. Sections were then
rinsed with water, counterstained using Mayer’s hematoxylin
solution (diluted 1:1 with water) (Sigma-Aldrich) for 1
minute, and mounted using Aquapolymount (Polyscience).
In total, two blocks from each of twenty tumors were
evaluated (ﬁve from each of the four treatment groups).
Images were captured in a blinded fashion using 20x
magniﬁcation objective of a Leica DMLB compound light
microscope ﬁtted with a Q imaging QICAM fast1394 digital
camera using Q-Capture software, depending on the size
of the tumor, certain sections were subdivided into one to
four ﬁelds of view. Hypoxic regions were identiﬁed by strong
brown reaction product, and necrotic regions were identiﬁed
as those adjacent to hypoxic zones and lacking intact, well-
deﬁned nuclei (as seen with hematoxylin staining). Optimas
6.0 software (Optimas, Houston) was used to quantify areas
of hypoxia and necrosis in each section and percentage of
hypoxia/necrosis or hypoxia and necrosis per section area
was calculated.
2.4. Quantiﬁcation of Tie2 Expression and Microvessel Density
(MVD). To evaluate Tie2 expression patterns as well as
determine MVD, two tissue blocks from each tumor were
assessed. Cryosections, 8μm thick, were cut using a cryostat
adjusted to −20◦C. Once cut, sections were stored at −80◦CJournal of Oncology 3
until further use. For immunoﬂuorescent staining, sections
were air dried at RT, ﬁxed in cold methanol/acetone (50:50)
for 10min at −20◦C, and then air dried. Then, sections
were rehydrated in PBS and blocked using 10% normal
goat serum (Sigma-Aldrich) for 1h at room temperature
followed by mouse anti-Tie2 (1:100; BD Biosciences) for 1h
at room temperature and incubation with goat antimouse
Cy3 conjugated secondary antibody for 20 minutes (1:200;
Jackson ImmunoResearch). Sections were blocked using
Dako protein-free block (Dako) for 15 minutes, incubated
overnightat4◦Cusingratanti-CD31antibody(1:50;Hycult
Biotechnology), followed by donkey antirat FITC secondary
antibody for 30 minutes (1:100; Jackson ImmunoResearch)
a n d2m i n u t e si nD A P I( 4  ,6-diamidino-2-phenylindole)
(Dako) nuclear stain. Slides were then washed brieﬂy in
water and mounted using Fluorescent Mounting media
(Dako). Entire sections were examined by epiﬂuorescence
microscopy using the 20x objective in a semiblinded fashion.
MVD was determined by dividing the total number of blood
vessels per ﬁeld of view, to obtain a value expressed as
number of blood vessels per mm2.
2.5. Quantiﬁcation of Blood Vessel Pericyte Coverage. To eval-
uate the degree of pericyte coverage of tumor blood vessels,
two blocks from each tumor were assessed. Cryosections,
8μm thick, were ﬁxed as previously described, then rehy-
drated in PBS, permeabilized using 0.05% Tween-PBS for 10
minutes and blocked using 10% normal goat serum (Sigma-
Aldrich) for 30 minutes at RT. Sections were incubated in
a mixture of rabbit anti-PDGFR-β (1:100; Cell Signaling
Technology) and biotinylated rat anti-CD31 (1:60; Hycult)
primary antibodies overnight at 4◦C .S e c t i o n sw e r ew a s h e d
in PBS and incubated in a mixture of goat antirabbit
secondary antibody conjugated to Cy3 (1:200; Jackson
ImmunoResearch) and streptavidin conjugated to Alexa350
(1:150; Invitrogen) for 40 minutes at room temperature
followed by rabbit anti-desmin primary antibody for 30
minutes (1:100; Abcam, Cambridge, Mass, USA) conju-
gated to Alexa488 using the rabbit antibody labeling kit
according to manufacturer’s protocol (Invitrogen). Sections
were mounted in Fluorescent Mounting Media (Dako) and
examined using epiﬂuorescence microscopy as previously
described. Five random ﬁelds were captured, and blood ves-
sels were enumerated as CD31positive/desminpositive/PDGFR-
βpositive or CD31positive/desminnegative/PDGFR-βnegative and
expressed as percentage per section.
2.6. Measurement of VEGF Levels in Tumor Xenograft Lysates.
Commercially available human and mouse VEGF ELISA kits
(both R & D Systems) were used to quantify VEGF levels in
lysed tumor xenografts from each of the treatment groups
(control, TekdeltaFc, LDM CTX and TekdeltaFc + LDM
CTX). Brieﬂy, frozen tumor pieces (3–5 per group) were
defrosted on ice and lysed using a disposable tissue grinder
and cell lysis buﬀer (Cell Signaling). Protein was collected as
previously described and VEGF ELISA performed according
to the manufacturer’s protocol. Values were expressed rela-
tive to total tumor protein.
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Figure 1: In vivo xenografts of human melanoma cancer cells
treated with TekdeltaFc and LDM CTX. Relative tumor growth for
each treatment group: Control, TekdeltaFc, low-dose metronomic
cyclophosphamide (LDM CTX), and combination for two weeks.
There were no statistically signiﬁcant diﬀerences in tumor growth
between treatment groups at any time points (P>0.05).
2.7.StatisticalAnalysis. Calculationofpreliminarysummary
statistics such as mean, standard deviation, and standard
error was completed using Microsoft Excel (Microsoft).
On all samples, Grubbs’ test, also called the ESD method
(extreme studentized deviate), was used to determine sig-
niﬁcant outliers. Once outliers, if any, were identiﬁed and
omitted from the analysis; ANOVA was performed to
determine the signiﬁcance within and between groups (P<
0.05).Further,theleastsigniﬁcantdiﬀerence(Tukey)testwas
used if there was signiﬁcant diﬀerence between groups. Data
were presented as mean and standard error.
3. Results
3.1. Eﬀects of LDM CTX and TekdeltaFc in Melanoma
Xenografts. While CTX LDM and TekdeltaFc showed a
reduction in tumor growth compared to control, these
diﬀerences were not statistically signiﬁcant (Figure 1; P>
0.05). Surprisingly, there was also no additive eﬀect when
CTX LDM and TekdeltaFc were combined, as this dual
target antiangiogenic regime also had no signiﬁcant eﬀect
on tumor growth compared to control at any time point
(Figure 1; P>0.05). When tumor sections were evaluated
f o rc e l l u l a rr e s p o n s e s( Figure 2(a)), we found no signiﬁcant
diﬀerences in the proportions of viable or hypoxic regions
between treatment groups (Figure 2(b); P>0.05). However,
signiﬁcantly lower amounts of tissue necrosis, and necrosis
plus hypoxia were observed in tumors treated with CTX
LMD when compared to control and combination-treated
tumors (Figure 2(b); P<0.05).
We quantiﬁed microvessel density (MVD) as well as the
proportion of Tie2-negative vessels in tumor xenograft sec-
tions stained for CD31 and Tie2 (Figure 3(a)). The average
number of Tie2 negative blood vessels was about 12.5%,
which conﬁrmed our previous ﬁnding of Tie2 vascular
heterogeneity in melanoma [12]; there were no signiﬁcant
diﬀerences between treatment groups (P>0.05). Although4 Journal of Oncology
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Figure 2: Quantiﬁcation of hypoxic and necrotic areas in tumor xenografts treated with TekdeltaFc and LDM CTX. (a) Representative low
(5x, left) and high (20x, right) magniﬁcation images of hypoxia immunostaining for Hypoxyprobe adducts and tissue necrosis in tumor
sections. Dark brown areas are hypoxic (arrow), light brown areas are viable tumor (arrowhead), and areas lacking brown reaction product
and containing degraded nuclei are necrotic tissue (asterisk). (b) Quantiﬁcation of the mean percent viable tissue, hypoxia, necrosis, or
hypoxia and necrosis in each treatment group, showing signiﬁcant diﬀerences in proportions of necrotic, and necrotic plus hypoxic areas in
LDM-CTX-treated tumors compared to control and combination (∗P<0.05).
decreased MVD was observed in LDM-CTX-treated tumors
compared to TekdeltaFc treatment group, this was not
statistically signiﬁcant (P>0.05) (Figure 3(b)).
3.2. TekdeltaFc Signiﬁcantly Increased Pericyte Coverage of
Tumor Blood Vessels Compared to Low-Dose CTX Treatment.
Triple immunoﬂuorescence was utilized on frozen sections
of xenografts with antibodies to desmin and PDGFR-β
to detect vascular mural cells [25]. Vessels were catego-
rized as Desmin/PDGFR-βpositive or Desmin/PDGFR-βnegative
(Figure 4(a)). We observed a statistically signiﬁcant diﬀer-
ence (P<0.05) between treatment groups. TekdeltaFc-
treated tumors had statistically signiﬁcant (P<0.05)
increased pericyte coverage compared to all other groups
(Figure 4(b)).
3.3. TekdeltaFc and LDM CTX Increased VEGF Expression.
Tumor pieces from each treatment group were lysed and
VEGF expression analyzed and expressed as pg/mL, normal-
ized for total protein in the tumor lysate. Human VEGF
levels were signiﬁcantly increased (P<0.05) in TekdeltaFc
and LDM CTX combined treated tumors compared to all
of the other treatment groups. In addition, human VEGF
concentration was signiﬁcantly higher (P<0.05) in LDM
CTX compared to control group (Figure 5(a)). Although
murine VEGF levels were highest in LDM-CTX-treated
tumors, ANOVA showed that overall there were no sig-
niﬁcant diﬀerences in murine VEGF levels (P>0.05;
Figure 5(b)).
4. Discussion
Tumor angiogenesis is an attractive therapeutic target, since
it is shared by most commonly occurring, and perhaps all,
types of human cancers [26]. Considering the importance of
vascular growth in tumor progression, approaches targeting
tumor endothelium using antiangiogenic therapies mayJournal of Oncology 5
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Figure 3: Dual immunoﬂuorescence staining for CD31 and Tie2. (a) Tie2 was ﬂuorescently labeled red using Cy3 while CD31 was
ﬂuorescently labeled green using FITC. Representative Tie2-positive blood vessels are marked with an asterisk while representative Tie2-
negativebloodvesselsarelabeledwitharrows.(b)Quantiﬁcationofaveragebloodvesseldensities(asnumberofCD31-positivevessels/mm2)
between treatment groups. There were no statistically signiﬁcant diﬀerences in blood vessel density between diﬀerent treatment groups
(P>0.05).(c)Quantiﬁcationof%Tie2-negativebloodvesselsintumorxenograftstreatedwithTekdeltaFcand/orLDMCTX.Graphdepicts
the average % of Tie2-negative blood vessels per treatment group; the diﬀerence between groups is not statistically signiﬁcant (P>0.05).
provide a long-term and more eﬀective control of disease
compared to cytotoxic chemotherapy. One of the advantages
of using antiangiogenic agents is that, under physiological
conditions, normal endothelial cells are quiescent compared
to tumor endothelial cells that are actively proliferating
and migrating, which minimizes possible side eﬀects on
normal endothelium [27]. In addition, endothelial cells are
genetically more stable than cancer cells and antiangiogenic
agent delivery is less complicated by not having to penetrate
large bulky masses. Finally, antiangiogenic therapies can
have diﬀerent modes of action—interfering with angiogenic
ligands, their receptors or downstream signaling, upreg-
ulation/delivery of endogenous inhibitors, or by directly
aﬀecting tumor vasculature [28]. More recently, it has
become apparent that cancer cells recruit a variety of bone-
marrow-derived cells which are also able to contribute to the
vasculature in direct and indirect ways [29].
The mechanism of action of TekdeltaFc (the extracellular
domain of murine Tie2/Tek receptor fused to the Fc portion
of murine IgG) involves binding with high avidity to both
Ang1 and Ang2 [16]. A similar inhibitory molecule, ExTek,
was shown to function as a potent inhibitor of Tie2 by
sequestering available angiopoietin, and by binding to Tie2
receptors, inhibiting phosphorylation and downstream
signaling molecules related to cell survival [30–32].
Interestingly, ExTek decreased the number of lung metastasis
in a murine melanoma model [33]. Other studies employing
diﬀerent versions of the Tie2 extracellular domain as an
inhibitor achieved similar eﬀects in diﬀerent tumor models
[34–36].
In our study, while LDM CTX had a more profound
eﬀect on tumor blood vessel density compared to TekdeltaFc
treatment, these diﬀerences were not signiﬁcant. LDM CTX
may have had an indirect eﬀect on tumor growth by signiﬁ-
cantly decreasing the mobilization of circulating endothelial
cells from the bone marrow, as previously reported [37].
Interestingly, treatment of tumors with these antiangiogenic
agents did not result in increased hypoxia/necrosis of the
tumor tissue. This could be explained by some of our
previous work which showed that WM239 cells can develop
reduced vascular dependence and therefore enhanced sur-
vival even if their blood vessel density decreases [38]o r
by the fact that reduced vascular density actually represents
a “normalization” of the vascular bed, accompanied by6 Journal of Oncology
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Figure 4: Immunostaining of blood vessels and pericytes in treated tumors. (a) Images show blood vessels immunoﬂuorescently stained
using antibodies to CD31 (Alexa 350; blue), desmin (Alexa 488; green), PDGFR-β (Cy3; red), and overlay of CD31/desmin/PDGFR-β.
Asterisk marks blood vessel negative for mural cells (neither desmin nor PDGFR-β) while arrow indicates blood vessel with positive mural
cell markers (desmin and PDGFR-β staining). (b) Quantiﬁcation of blood vessel pericyte coverage in tumors treated with TekdeltaFc and/or
LDM CTX. The percentage of “stable” blood vessels with pericyte coverage was signiﬁcantly diﬀerent between TekdeltaFc and all other
treatment groups (∗P<0.05).Journal of Oncology 7
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Figure 5: Expression of VEGF in tumor xenografts. Concentration
of VEGF levels in tumor lysates measured by ELISA and expressed
a sp g / m Ln o r m a l i z e dt op r o t e i nc o n t e n ti nt h et u m o rl y s a t e .
(a) There were signiﬁcant diﬀerences in human VEGF levels
between treatment groups (∗P<0.05). The lowest human VEGF
concentration was detected in control tumors while the highest
VEGF concentration was detected in combined treatment group,
showing that TekdeltaFc and LDM CTX therapy both individually
and in combination signiﬁcantly upregulated melanoma cell VEGF
expression. (b) There were no signiﬁcant diﬀerences in murine
VEGF between treatment groups (P>0.05).
improved perfusion [39]. Such mechanisms are consistent
with the fact that LDM-CTX-treated tumors had the lowest
amount of necrotic tissue compared to control or combined
treatment groups.
WealsoobservedthatTekdeltaFcalonecausedsigniﬁcant
increases in desmin/PDGFR-β dual positive pericyte cover-
age of blood vessels compared to control, LDM CTX, or
combination therapies. Antiangiogenic therapies have been
previously shown to improve response to chemotherapy
by inducing maturation of the blood vessels via increasing
pericyte coverage [27, 40] .T h e r ei sc o n s i d e r a b l ev a r i a b i l i t y
in pericyte characteristics between tumor types, with some
studies reporting that mature pericytes are PDGFR-β nega-
tive and desmin positive [40], while other studies report that
tumor pericyte populations can have overlapping markers
[41]. Interestingly, PDGFR-β-positive/desmin-negative cells
were more likely to be detached from adjacent vessels [41].
In abnormal tumor vasculature, VEGF induces expression
of Ang-2 from endothelial cells in the microvasculature
[42, 43]. By binding to Tie2, Ang-2 becomes an autocrine
regulator of endothelial cell function; whether it acts as an
agonist [42, 44] or antagonist [45]i sc o n t e x td e pe n d e n t[ 46].
It is now known that in vitro Ang-2 inhibits the stabilizing
eﬀects of Ang-1, but weakly activates Tie2 if Ang-1 is absent
[47].Inourtumormodel,TekdeltaFclikelycausedsequester-
ing of abundantly expressed Ang-2, thus allowing Ang-1 to
bind and phosphorylate Tie2, hence the observed increase in
pericytecoverage.Vessel“normalization”hasbeenassociated
with improved response to cytotoxic chemotherapy [21, 48],
thus employing CTX at a maximally tolerated dose rather
than a metronomic dose might be more eﬀective.
Both TekdeltaFc and LDM CTX alone caused signiﬁcant
decreases in tumor volume at earlier time points, but
they failed to do so after two weeks of treatment. This
could be due to the fact that most advanced malignant
tumors produce multiple angiogenic factors, and so tar-
geting only angiopoietins (in TekdeltaFc treated tumors)
or only VEGF (in LDM-CTX-treated tumors) may not
be adequate for complete tumor control [8, 28, 49, 50].
Tumors may also have become resistant to TekdeltaFc or
LDM CTX, allowing them to regrow after initial inhibition.
Interestingly, tumor xenografts treated with TekdeltaFc and
LDM CTX combination therapy grew at the same rate as
controls, suggesting potential interference between these two
therapies. This is in contrast to results with a neutralizing
antibody against Ang2, which had potent antitumor eﬀects
in xenograft models, especially when combined with VEGF-
targeted therapy [21]. Diﬀerences from our study may be
due to the fact that, unlike anti-Ang2 antibody, TekdeltaFc
aﬀects Ang1 and Ang2 signaling. Diﬀerences may also be
due to cancer type, as melanoma was not evaluated in the
anti-Ang2 antibody study. Thus, although combination of
antiangiogenic therapies is becoming a common practice
[2, 22, 50, 51], our studies provide evidence that interactions
may be complex and tumor type dependent.
Surprisingly, treated tumors in our study contained sig-
niﬁcantly higher levels of human VEGF than control tumors,
andcombinedtreatedtumorscontainedthehighestamount,
consistent with a proangiogenic environment observed at
the end of this trial. One of the modes of resistance to
antiangiogenic therapy, usually occurring after a transient
response phase, is upregulation of alternative proangiogenic
pathways in tumors, such as ﬁbroblast growth factor 1 and
2, ephrin A1, or Ang 1. These presumably compensate
for the inhibited pathway and allow tumor regrowth [52].
In one such study, patients treated with VEGFR inhibitor
cediranib had an increase in FGF2 expression in their
relapse phase after successful but transient response [53]. It
has also been shown in clinical trials that tyrosine kinase
inhibitorscantransientlyincreasethelevelsofproangiogenic
factors, such as VEGF [54], as we observed in our present
study. In fact, increases in proangiogenic factor VEGF in8 Journal of Oncology
the presence of antiangiogenic Tie2 inhibitor probably
account for the lack of an observed decrease in blood vessel
density in our treated tumors. Collectively, these data sup-
port the idea that two diﬀerent antiangiogenic therapies may
interact to stabilize the microvasculature, thus preventing
vessel regression and tumor inhibition, an outcome that
suggests that caution should be taken in designing such
antiangiogenic combinations.
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